FREE Daily Stock Alerts From Stock-PR.com
Dot Hill Systems Corp. (Nasdaq:HILL) announced earlier this month a new OEM agreement with Wortmann AG, a Germany-based IT solutions provider specializing in small to medium business and home user markets through the European distribution channel. Wortmann's success is founded on the evaluation, development and integration of cost effective IT solutions covering mobile, desktop, server, storage and display technologies through their long established Terra brand portfolio. With more than 24 years of experience, Wortmann is one of the leading IT companies in Germany with subsidiaries in Austria, Switzerland, France, Netherlands and Asia.
Dot Hill Systems Corp. provides entry-level and midrange storage systems and enterprise server software for organizations requiring networked storage and data management solutions in open systems architecture. Its storage solutions consist of integrated hardware, firmware, and software products employing a modular system that allows end-users to add various capacity or data protection schemes as needed.
Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.
Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.
Worldwide, breast cancer comprises 10.4% of all cancer incidence among women, making it the most common type of non-skin cancer in women and the fifth most common cause of cancer death. In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths). Breast cancer is about 100 times more common in women than in men, although males tend to have poorer outcomes due to delays in diagnosis
Breast cancer is an uncontrolled growth of breast cells. Cancer occurs as a result of mutations, or abnormal changes, in the genes responsible for regulating the growth of cells and keeping them healthy. The genes are in each cell’s nucleus, which acts as the “control room” of each cell. Normally, the cells in our bodies replace themselves through an orderly process of cell growth: healthy new cells take over as old ones die out. But over time, mutations can “turn on” certain genes and “turn off” others in a cell. That changed cell gains the ability to keep dividing without control or order, producing more cells just like it and forming a tumor.
To learn more about PWRM visit: http://www.Power3Medical.com
Arrowhead Research Corp. (Nasdaq:ARWR) announced this month that it has completed IP cooperation and license agreements with Samsung Electronics Co., Ltd. Under the agreements: Unidym licensed to Samsung patents covering CNT materials, including fundamental patents on CNT compositions of matter, synthesis of CNTs, processing of CNTs, ink formulations, and transparent conductive films, Unidym transferred certain patent rights to Samsung, primarily related to electronic devices incorporating CNTs. Samsung granted back to Unidym licenses to sell products under the transferred patent rights & Unidym and Samsung will continue to work together to develop and commercialize CNT-based products.
Arrowhead Research Corporation, through its subsidiaries, identifies advances in nanotechnology and matches them with product development opportunities in high-growth markets, focusing on the electronics and biotech industries. It focuses on developing, commercializing, and licensing a range of nanotechnology products and applications.
GreenHouse Holdings, Inc. a leading provider of energy efficiency solutions and sustainable infrastructure products, recently announced that it has been engaged to utilize Southern California Edison’s (SCE) Automated Demand Response (Auto-DR) program in Gulfstream Aerospace Corporation’s Long Beach, CA facility. GreenHouse is a qualified service provider of SCE’s Auto-DR program, providing site assessment, feasibility studies, project development, engineering, and installation of enabling technologies and complete processing of all incentives.
The Auto-DR program offers significant financial incentives and technical support to SCE customers with automated load control systems that participate in demand response events. Auto-DR uses control systems to automatically achieve specified energy demand reductions (kW and duration) during periods of peak energy consumption. In utilizing the Auto-DR system, Gulfstream will reduce electric consumption during costly peak energy periods when the demand is highest. Additionally, the system provides Gulfstream the ability to reduce operating costs by curtailing the use and purchase of electricity. Gulfstream will then receive financial incentives from SCE.
“Auto-DR is just one of the innovative services Greenhouse offers to help our clients reduce energy consumption by deploying state-of-the-art technology,” says Rob Davis, Vice President of GreenHouse Holdings, Inc. “We are truly honored to be selected by Gulfstream and we are looking forward to the Auto-DR project as the first of many services offered in support of Gulfstream’s corporate energy stewardship initiatives. This project goes to the heart of Greenhouse’s mission to deliver sustainable solutions that reduce energy consumption with a positive return on investment.”
GreenHouse is a leading integrator of some of the world’s most innovative environmental sustainability systems, eco-friendly infrastructure, and public safety strategies and technologies. GRHU designs their systems to achieve solutions that are financially sound and environmentally sustainable. GRHU's mission is to create and sustain a greener, safer world for today – and for the future.
To learn more about GRHU visit: http://www.greenhouseintl.com
AVI Biopharma, Inc. (Nasdaq:AVII) announced recently the appointment of Chris Garabedian as CEO and president effective Jan. 1, 2011. Garabedian, who has served as a director since June, will continue as a member of the board. J. David Boyle II, who held the post of interim CEO and president, will continue in his role as CFO and senior vice president.
AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company’s products under development comprise AVI-4658, which has completed Phase I human clinical trials to restore, prevent, or slow deterioration of muscle function; and AVI-5038, a preclinical stage product that is designed to skip exon 50, and overcome the mutational block and restore dystrophin expression.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received ten thousand dollars in cash and anticipates another ten thousand dollars in cash from the company for 60 days of advertisement services for Green House Holdings, Inc. (OTCQB:GRHU). In addition to the cash, Crown Equity Holdings Inc. (OTCPK:CRWE) also anticipates receiving 20,000 shares of 144 restricted stocks from a third party. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.